RxSight, Inc. (RXST)
| Market Cap | 328.59M |
| Revenue (ttm) | 15.27M |
| Net Income (ttm) | 37.27M |
| Shares Out | 26.52M |
| EPS (ttm) | 1.41 |
| PE Ratio | 8.82 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,781 |
| Open | 12.61 |
| Previous Close | 12.51 |
| Day's Range | 12.39 - 13.08 |
| 52-Week Range | 11.19 - 19.67 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 20.60 (+66.3%) |
| Est. Earnings Date | Nov 15, 2021 |
About RXST
RxSight is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Our proprietary RxSight Light Adjustable Lens system (“RxSight system”), comprised of our RxSight Light Adjustable Lens (“LAL”), RxSight Light Delivery Device (“LDD”) and accessories, is the first and only commercially available intraocular lens (“IOL”) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. With the RxSight system, the surgeon per...
Financial Performance
In 2020, RxSight's revenue was $14.68 million, an increase of 554.98% compared to the previous year's $2.24 million. Earnings were $27.58 million, a decrease of -78.15%.
Financial StatementsNews
RxSight Reports Second Quarter 2021 Financial Results
ALISO VIEJO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported finan...
RxSight Announces Updated Date for Reporting Second Quarter 2021 Financial Results on September 9, 2021
ALISO VIEJO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ: RXST) an ophthalmic medical device company, today announced an updated date for reporting second quarter 2021 financial re...
RxSight to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Health...
RxSight to Report Second Quarter 2021 Financial Results on September 7, 2021
ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the...
Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTech ...
RxSight, Inc. Expands Commercial Leadership with Addition of Steve Everly as Vice-President of U.S. Sales
ALISO VIEJO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company, today announced that Steve Everly has joined the company as its Vice Presiden...
RxSight Announces Appointments to its Board of Directors
ALISO VIEJO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the appointment of three new members to its Board of Directors effective as of...
RxSight, Inc. Announces Pricing of Initial Public Offering
RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial...
RxSight IPO Registration Document (S-1)
RxSight, Inc. has filed to go public with an IPO on the NASDAQ.